生物制剂治疗银屑病及在相关皮肤病中的研究进展
Research Progress of Biologics in the Treat-ment of Psoriasis and Related Skin Diseases
DOI: 10.12677/ACM.2023.1361433, PDF,   
作者: 魏子芝：青海大学研究生院，青海?西宁 ；郭 砚*：青海大学附属医院皮肤性病科，青海?西宁
关键词: 生物制剂；炎症细胞因子；白细胞介素12、23、17、22；皮肤病；综述；Biologics； Inflammatory Cytokine； Interleukin 12； 23； 17； 22； Dermatosis； Review
摘要: 银屑病作为炎症性和系统性疾病，它具有起病慢和易复发的特点，遗传、免疫和环境三种因素共同作用介导了银屑病的发生。局限或广泛分布的鳞屑样红斑或斑块为其典型的临床表现。银屑病的治疗包括外用药物、系统药物、物理治疗以及生物制剂，这些治疗主要改善其症状来提高患者的生活质量。目前很多临床试验表明，对于常规系统治疗无效或耐受性差的中至重度银屑病和(或)银屑病性关节炎患者可使用生物制剂，为患者能够带来持久疗效、长期安全和使用便捷等。生物制剂主要是针对炎症细胞因子，如TNF-α、IL-12/23和IL-17A等发挥作用的，也就是主要的免疫因素，阻断其发展，疗效显著。主要的生物制剂有乌司奴单抗、司库奇尤单抗、利妥昔单抗等，目前一些新的数据表明，生物制剂对共同炎症细胞因子的疾病也是有效果的，如寻常型天疱疮、玫瑰糠疹、扁平苔癣、毛发红糠疹和系统性硬化症患者是有效的。
Abstract: As an inflammatory and systemic disease, psoriasis, which induced by genetic, immune and envi-ronmental factors, it is characterized by slow onset and easy recurrence. The typical clinical mani-festations are squamous erythema or plaques, localized or widespread. Psoriasis treatment in-cludes topical medications, systemic medications, physical therapy, and biologics that improve symptoms and improve quality of life. Currently, many clinical trials have shown that biologics can be used clinically, particularly for patients with moderate to severe psoriasis and/or psoriatic ar-thritis who do not respond to conventional systemic therapy or are poorly tolerated. Biologics can bring lasting efficacy, long-term safety and ease of use for patients. Biological agents mainly target inflammatory cytokines, such as TNF-α, IL-12/23 and IL-17A, which are the main immune factors, and block their development, with significant effect. The main biologics include ulsinumab, scucci-umab, rituximab, etc. At present, some new data show that biologics are also effective for diseases with common inflammatory cytokines, such as pemphigus vulgaris, pityriasis rosea, lichenus planus, pityriasis rufuris pilaris and systemic sclerosis patients.
文章引用：魏子芝, 郭砚. 生物制剂治疗银屑病及在相关皮肤病中的研究进展[J]. 临床医学进展, 2023, 13(6): 10240-10247. https://doi.org/10.12677/ACM.2023.1361433

参考文献

[1] Yu, N., Wang, S., Song, X., et al. (2018) Low-Dose Radiation Promotes Dendritic Cell Migration and IL-12 Production via the ATM/NF-κB Pathway. Radiation Research, 189, 409-417. [Google Scholar] [CrossRef] 
[2] 李静. 银屑平丸对银屑病样小鼠模型血清中IL-4和IL-12表达水平的影响[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2022.[CrossRef] 
[3] 张良芬, 吴勤学, 王群. 银屑病患者血清中细胞因子状态的研究[J]. 中华皮肤科杂志, 2001, 34(2): 101-102.
[4] Quatrini, L.,Vacca, P., Tumino, N., et al. (2021) Glucocorticoids and the Cytokines IL-12, IL-15, and IL-18 Present in the Tumor Microenvironment Induce PD-1 Ex-pression on Human Natural Killer Cells. Journal of Allergy and Clinical Immunology, 147, 349-360. [Google Scholar] [CrossRef] [PubMed]
[5] Naoya, K., Shohei, K., Shin, H., et al. (2022) Walls Teichoic Ac-id-Dependent Phagocytosis of Intact Cell Walls of Lactiplantibacillus plantarumwall Elicits IL-12 Secretion from Mac-rophages. Frontiers in Microbiology, 13, Article 986396. [Google Scholar] [CrossRef] [PubMed]
[6] Kaveh, A., Karen, L., Mehrnoosh, A., Elizabeth, M.H., Larry, L., Nevil, J. and Eric, O. (2022) Dendritic Cells Trigger IFN-γ Secretion by NK Cells Independent of IL-12 and IL-18. European Journal of Immunology, 52, 1431-1440. [Google Scholar] [CrossRef] [PubMed]
[7] Avishai, S., Harry, P., Roybal, K.T. and Lanier, L.L. (2022) Differential IL-12 Signaling Induces Human Natural Killer Cell Activating Receptor-Mediated Ligand-Specific Expansion. Journal of Experimental Medicine, 219, e20212434. [Google Scholar] [CrossRef] [PubMed]
[8] Ann, R., Brown, B.S., Stofega, M., et al. (2022) Targeting IRAK3 for Degradation to Enhance IL-12 Pro-Inflammatory Cytokine Production. ACS Chemical Biology, 17, 1315-1320. [Google Scholar] [CrossRef] [PubMed]
[9] Viola, N.T., Glassbrook, J.E., Kalluri, J.R., et al. (2022) Evalua-tion of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Frontiers in Micro-biology, 13, Article 870110. [Google Scholar] [CrossRef] [PubMed]
[10] Mahung, C., Stepp, W.H., Long, C., et al. (2022) Early expres-sion of IL-10, IL-12, ARG1 and NOS2 Genes in Peripheral Blood Mononuclear Cells Synergistically Correlate with Pa-tient Outcome after Burn Injury. Journal of Trauma and Acute Care Surgery, 93, 702-711. [Google Scholar] [CrossRef] 
[11] Kawamoto-Miyamoto, N., Hosoda, H., Miyoshi, K. and Nomoto, K. (2022) Glutamate in the Medium of Lactiplantibacillus plantarum FL-664 Affects the Production of IL-12(p40) on Murine Spleen Cells. Bioscience, Biotechnology, and Biochemistry, 86, 535-542. [Google Scholar] [CrossRef] [PubMed]
[12] Merkley, S.D., Goodfellow, S.M., Guo, Y., Wilton, Z.E.R., Byrum, J.R., Schwalm, K.C., Dinwiddie, D.L., Gullapalli, R.R., Deretic, V., Jimenez Hernandez, A., Bradfute, S.B., Julie, I.G. and Castillo, E.F. (2022) Non-Autophagy Role of Atg5 and NBR1 in Unconventional Secretion of IL-12 Prevents Gut Dysbiosis and Inflammation. Journal of Crohn’s and Colitis, 16, 259-274. [Google Scholar] [CrossRef] [PubMed]
[13] Vincken, N.L.A., Welsing, P.M.J., Silva-Cardoso, S.C., et al. (2022) Suppression of IL-12/IL-23 p40 Subunit in the Skin and Blood of Psoriasis Patients by Tofacitinib Is Dependent on Ac-tive Interferon-γ Signaling in Dendritic Cells: Implications for the Treatment Of Psoriasis and Interferon-Driven Diseases. Experimental Dermatology, 31, 962-969. [Google Scholar] [CrossRef] [PubMed]
[14] Floss, D.M., Schröder, J., Franke, M. and Scheller, J. (2015) Insights into IL-23 Biology: From Structure to Function. Cytokine & Growth Factor Reviews, 26, 569-78. [Google Scholar] [CrossRef] [PubMed]
[15] Yawalkar, N., Tscharner, G.G., Hunger, R.E. and Hassan, A.S. (2009) Increased Expression of IL-12p70 and IL-23 by Multiple Dendritic Cell and Macrophage Subsets in Plaque Pso-riasis. Journal of Dermatological Science, 54, 99-105. [Google Scholar] [CrossRef] [PubMed]
[16] Nograles, K.E., Brasington, R.D. and Bowcock, A.M. (2009) New Insights into the Pathogenesis and Genetics of Psoriatic Arthritis. Nature Clinical Practice Rheumatology, 5, 83-91. [Google Scholar] [CrossRef] [PubMed]
[17] Schurich, A., Raine, C., Morris, V. and Ciurtin, C. (2018) The Role of IL-12/23 in T Cell-Related Chronic Inflammation: Implications of Immunodeficiency and Therapeutic Blockade. Rheumatology, 57, 246-254. [Google Scholar] [CrossRef] [PubMed]
[18] Morelli, M., Galluzzo, M., Scarponi, C., et al. (2022) Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis. Vaccines, 10, Article 1977. [Google Scholar] [CrossRef] [PubMed]
[19] Whitley, S., Li, M., Kashem, S.W., et al. (2022) Local IL-23 Is Required for Proliferation and Retention of Skin-Resident Memory T17 Cells. Science Immunology, 7, eabq3254. [Google Scholar] [CrossRef] [PubMed]
[20] Xiong, D.-K., Shi, X., Han, M.-M., et al. (2022) The Regulatory Mechanism and Potential Application of IL-23 in Autoimmune Diseases. Frontiers in Pharmacology, 13, Article 982238. [Google Scholar] [CrossRef] [PubMed]
[21] Noack, M. and Miossec, P. (2022) Synoviocytes and Skin Fibro-blasts Show Opposite Effects on IL-23 Production and IL-23 Receptor Expression during Cell Interactions with Immune Cells. Arthritis Research & Therapy, 24, Article No. 220. [Google Scholar] [CrossRef] [PubMed]
[22] 张洋洋, 王刚. IL-12/23抑制剂乌司奴单抗在银屑病治疗中的应用[J]. 中国皮肤性病学杂志, 2020, 34(4): 454-457. [Google Scholar] [CrossRef] 
[23] Koutruba, N., Emer, J. and Lebwohl, M. (2010) Review of Ustekinumab, an Interleukin-12 and Interleukin-23 Inhibitor Used for the Treatment of Plaque Psoriasis. Therapeutics and Clinical Risk Management, 6, 123-141. [Google Scholar] [CrossRef] 
[24] Leonardi, C.L., Kimball, A.B., Papp, K.A., et al. (2008) Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1). The Lancet, 371, 1665-1674. [Google Scholar] [CrossRef] 
[25] Papp, K.A., Langley, R.G., Lebwohl, M., et al. (2008) Effi-cacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). The Lancet, 371, 1675-1684. [Google Scholar] [CrossRef] 
[26] Zhu, X., Zheng, M., Song, M., et al. (2013) Efficacy and Safety of Ustekinumab in Chinese Patients with Moderate to Severe Plaque-Type Psoriasis: Results from a Phase 3 Clin-ical Trial (LOTUS). Journal of Drugs in Dermatology, 12, 166-174.
[27] Griffiths, C.E.M., Strober, B.E., van de Kerkhof, P., et al. (2010) Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. The New Eng-land Journal of Medicine, 362, 118-128. [Google Scholar] [CrossRef] 
[28] Rich, P., Bourcier, M., Sofen, H., Fakharzadeh, S., Wasfi, Y., Wang, Y., Kerkmann, U. Ghislain, P.-D., Poulin, Y., on Behalf of the PHOENIX 1 Investigators (2014) Ustekinumab Im-proves Nail Disease in Patients with Moderate-to-Severe Psoriasis: Results from PHOENIX 1. British Journal of Der-matology, 170, 398-407. [Google Scholar] [CrossRef] [PubMed]
[29] McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., et al. (2013) Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial. The Lancet, 382, 780-789. [Google Scholar] [CrossRef] 
[30] Ritchlin, C., Rahman, P., Kavanaugh, A., et al. (2014) Effi-cacy and Safety of the Anti-IL-12/23 p40 Monoclonal Antibody, Ustekinumab, in Patients with Active Psoriatic Arthritis Despite Conventional Non-Biological and Biological Anti-Tumour Necrosis Factor Therapy: 6-Month and 1-Year Re-sults of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled, Randomised PSUMMIT 2 Trial. Annals of the Rheumatic Diseases, 73, 990-999. [Google Scholar] [CrossRef] [PubMed]
[31] Facheris, P., Valenti, M., Pavia, G., Elena, G., Alessandra, N., Riccardo, G. and Antonio, C. (2020) Brodalumab: A New Way to Inhibit IL-17 in Psoriasis. Dermatologic Therapy, 33, e13403. [Google Scholar] [CrossRef] [PubMed]
[32] Guo, X.M., Mao, X.R., Tian, D., et al. (2022) Cryptococcus neoformans Infection Induces IL-17 Production by Promoting STAT3 Phosphorylation in CD4+ T Cells. Frontiers in Immunology, 13, Article ID: 872286. [Google Scholar] [CrossRef] [PubMed]
[33] Daudén, E., Castañeda, S., Suárez, C., et al. (2013) Clinical Practice Guideline for an Integrated Approach to Comorbidity in Patients with Psoriasis. Journal of the European Acad-emy of Dermatology and Venereology, 27, 1387-1404. [Google Scholar] [CrossRef] [PubMed]
[34] Wilson, N.J., Boniface, K., Chan, J.R., et al. (2007) Development, Cytokine Profile and Function of Human Interleukin 17-Producing Helper T Cells. Nature Immunology, 8, 950-957. [Google Scholar] [CrossRef] [PubMed]
[35] Miossec, P. and Kolls, J.K. (2012) Targeting IL-17 and TH17 Cells in Chronic Inflammation. Nature Reviews Drug Discovery, 11, 763-776. [Google Scholar] [CrossRef] [PubMed]
[36] Kryczek, I., Bruce, A.T., Gudjonsson, J.E., et al. (2008) Induction of IL-17+ T Cell Trafficking and Development by IFN-Gamma: Mechanism and Pathological Relevance in Psoriasis. The Journal of Immunology, 181, 4733-4741. [Google Scholar] [CrossRef] [PubMed]
[37] Lin, A.M., Rubin, C.J., Khandpur, R., et al. (2011) Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. The Journal of Immunology, 187, 490-500. [Google Scholar] [CrossRef] [PubMed]
[38] Deodhar, A., Mease, P.J., McInnes, I.B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L. and Fox, T. (2019) Long-Term Safety of Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spon-dylitis: Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data. Arthritis Research & Therapy, 21, Article No. 111. [Google Scholar] [CrossRef] [PubMed]
[39] Reich, K., Armstrong, A.W., Langley, R.G., et al. (2019) Guselkumab versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results from a Phase 3, Randomised Controlled Trial. The Lancet, 394, 831-839. [Google Scholar] [CrossRef] 
[40] Blauvelt, A. (2016) Safety of Secukinumab in the Treatment of Psoriasis. Expert Opinion on Drug Safety, 15, 1413-1420. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, H.N. and Huang, Y.H. (2020) Changes in Metabolic Parameters in Psoriatic Patients Treated with Secukinumab. Therapeutic Advances in Chronic Disease, 11. [Google Scholar] [CrossRef] [PubMed]
[42] Goldberg, I.M., Brooks, J.K., Ghita, I., et al. (2022) Oral and Cutaneous Pemphigus Vulgaris: An Atypical Clinical Presentation. General Dentistry, 70, 22-26.
[43] Singh, P.K., Das, S., Rai, G., et al. (2022) A Snapshot of T Cell Subset Cytokines in Pemphigus Vulgaris: A Cross-Sectional Study. Cu-reus, 14, e29890. [Google Scholar] [CrossRef] [PubMed]
[44] Alshami, M.L., Aswad, F. and Abdullah, B. (2022) A Clinical and Demographic Analysis of Oral Pemphigus Vulgaris: A Retrospective Cross-Sectional Study from 2001 to 2021. Health Science Reports, 5, e832. [Google Scholar] [CrossRef] [PubMed]
[45] Hudemann, C., Exner, Y., Pollmann, R., et al. (2023) IgG against the Mem-brane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pem-phigus Vulgaris. Journal of Investigative Dermatology, 143, 254-263. [Google Scholar] [CrossRef] [PubMed]
[46] Lin, X., Chen, M., Li, X., et al. (2022) Low SOCS3 Expression in CD4+ T Cells from Pemphigus Vulgaris Patients Enhanced Th1- and Th17-Cell Differentiation and Exacerbated Acan-tholysis via STAT Activation. Molecular Immunology, 150, 114-125. [Google Scholar] [CrossRef] [PubMed]
[47] Hutchison, D.M., Hosking, A.-M., Hong, E.M., et al. (2022) Mitochondrial Autoantibodies and the Role of Apoptosis in Pemphigus Vulgaris. Antibodies, 11, Article 55. [Google Scholar] [CrossRef] [PubMed]
[48] Hebert, V. and Joly, P. (2018) Rituximab in Pemphigus. Immunother-apy, 10, 27-37. [Google Scholar] [CrossRef] [PubMed]
[49] Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., et al. (2017) First-Line Rituximab Combined with Short-Term Prednisone versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial. The Lancet, 389, 2031-2040. [Google Scholar] [CrossRef] 
[50] Tan-Lim, R. and Bystryn, J.C. (1990) Effect of Plasmapher-esis Therapy on Circulating Levels of Pemphigus Antibodies. Journal of the American Academy of Dermatology, 22, 35-40. [Google Scholar] [CrossRef] [PubMed]

为你推荐